254 related articles for article (PubMed ID: 31655611)
1. PRMT1 expression in renal cell tumors- application in differential diagnosis and prognostic relevance.
Filipović J; Bosić M; Ćirović S; Životić M; Dunđerović D; Đorđević D; Živković-Perišić S; Lipkovski A; Marković-Lipkovski J
Diagn Pathol; 2019 Oct; 14(1):120. PubMed ID: 31655611
[TBL] [Abstract][Full Text] [Related]
2. Cytoplasmic expression of Twist1, an EMT-related transcription factor, is associated with higher grades renal cell carcinomas and worse progression-free survival in clear cell renal cell carcinoma.
Rasti A; Madjd Z; Abolhasani M; Mehrazma M; Janani L; Saeednejad Zanjani L; Asgari M
Clin Exp Med; 2018 May; 18(2):177-190. PubMed ID: 29204790
[TBL] [Abstract][Full Text] [Related]
3. Expression and clinical value of SALL4 in renal cell carcinomas.
Che J; Wu P; Wang G; Yao X; Zheng J; Guo C
Mol Med Rep; 2020 Aug; 22(2):819-827. PubMed ID: 32468053
[TBL] [Abstract][Full Text] [Related]
4. CD10+ and CK7/RON- immunophenotype distinguishes renal cell carcinoma, conventional type with eosinophilic morphology from its mimickers.
Yasir S; Herrera L; Gomez-Fernandez C; Reis IM; Umar S; Leveillee R; Kava B; Jorda M
Appl Immunohistochem Mol Morphol; 2012 Oct; 20(5):454-61. PubMed ID: 22417859
[TBL] [Abstract][Full Text] [Related]
5. Loss of PBRM1 and BAP1 expression is less common in non-clear cell renal cell carcinoma than in clear cell renal cell carcinoma.
Ho TH; Kapur P; Joseph RW; Serie DJ; Eckel-Passow JE; Parasramka M; Cheville JC; Wu KJ; Frenkel E; Rakheja D; Stefanius K; Brugarolas J; Parker AS
Urol Oncol; 2015 Jan; 33(1):23.e9-23.e14. PubMed ID: 25465300
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of epithelial-mesenchymal transition markers in clear cell renal cell carcinoma.
Xu H; Xu WH; Ren F; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
Aging (Albany NY); 2020 Jan; 12(1):866-883. PubMed ID: 31915310
[TBL] [Abstract][Full Text] [Related]
7. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
[No Abstract] [Full Text] [Related]
8. Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.
Tschirdewahn S; Panic A; Püllen L; Harke NN; Hadaschik B; Riesz P; Horváth A; Szalontai J; Nyirády P; Baba HA; Reis H; Szarvas T
Int J Cancer; 2019 Jul; 145(2):531-539. PubMed ID: 30650187
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
10. [Expression of GPNMB in renal eosinophilic tumors and its value in differential diagnosis].
Wang Y; Hou MY; Fu Y; Meng K; Wu HY; Chen J; Xu YM; Shi J; Fan XS
Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):358-363. PubMed ID: 36973196
[No Abstract] [Full Text] [Related]
11. Cathepsin K (Clone EPR19992) Demonstrates Uniformly Positive Immunoreactivity in Renal Oncocytoma, Chromophobe Renal Cell Carcinoma, and Distal Tubules.
Iakymenko OA; Delma KS; Jorda M; Kryvenko ON
Int J Surg Pathol; 2021 Sep; 29(6):600-605. PubMed ID: 33764165
[No Abstract] [Full Text] [Related]
12. Molecular Characterization of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-mesenchymal Transition Gene Expression Signature.
Nallandhighal S; Vince R; Karim R; Groves S; Stangl-Kremser J; Russell C; Hu K; Pham T; Cani AK; Liu CJ; Zaslavsky A; Mehra R; Cieslik M; Morgan TM; Palapattu GS; Udager AM; Salami SS
Eur Urol Oncol; 2022 Feb; 5(1):92-99. PubMed ID: 34840106
[TBL] [Abstract][Full Text] [Related]
13. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
[TBL] [Abstract][Full Text] [Related]
14. Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma.
Wang C; Dong K; Wang Y; Peng G; Song X; Yu Y; Shen P; Cui X
BMC Cancer; 2021 Aug; 21(1):890. PubMed ID: 34348693
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.
Fan B; Wang W; Zhang X; Sun M; Wang X; Chen Z; Liu W; Wang Q; Yu N; Li X
BMC Cancer; 2019 Jun; 19(1):534. PubMed ID: 31159774
[TBL] [Abstract][Full Text] [Related]
16. Kidney-specific cadherin correlates with the ontogenetic origin of renal cell carcinoma subtypes: an indicator of a malignant potential?
Horstmann M; Geiger LM; Vogel U; Schmid H; Hennenlotter J; Kuehs U; Merseburger AS; Kruck S; Stenzl A; Bedke J
World J Urol; 2012 Aug; 30(4):525-31. PubMed ID: 21928123
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers of epithelial-mesenchymal transition in localized, surgically treated clear-cell renal cell carcinoma.
Gasinska A; Jaszczynski J; Adamczyk A; Janecka-Widła A; Wilk W; Cichocka A; Stelmach A
Folia Histochem Cytobiol; 2018; 56(4):195-206. PubMed ID: 30569446
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
[TBL] [Abstract][Full Text] [Related]
19. Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.
Steffens S; Roos FC; Janssen M; Becker F; Steinestel J; Abbas M; Steinestel K; Wegener G; Siemer S; Thüroff JW; Hofmann R; Stöckle M; Schrader M; Hartmann A; Junker K; Kuczyk MA; Schrader AJ;
Virchows Arch; 2014 Oct; 465(4):439-44. PubMed ID: 25178561
[TBL] [Abstract][Full Text] [Related]
20. LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma.
Peng Y; Greenland NY; Lang UE; Stohr BA
Pathol Res Pract; 2022 Apr; 232():153831. PubMed ID: 35287088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
